Cannabinoid Derivative Composition for Higher Seizure Threshold
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid-based treatments for conditions like epilepsy lack efficacy and there is a need for more effective alternatives to traditional cannabinoids such as CBD, which do not bind to CB1 or CB2 receptors, offering minimal psychotropic effects.
Innovation Solution
A synthetic cannabinoid derivative, (1′R,2′R)-5′-methyl-4-(1-methyl-1H-pyrazol-4-yl)-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-2,6-diol, is developed, which can be administered through various routes and formulated into pharmaceutical compositions for treating conditions like epilepsy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cannabinoids like CBD are used for treatment, then psychotropic effects are minimized, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the molecular structure of CBD through substitution at the 4'-position with various groups (methyl, halogen, hydroxyl, alkoxy, etc.). This structural modification changes the pharmacological parameters of the compound, enabling it to bind to CB1 and CB2 receptors while maintaining therapeutic benefits and reducing unwanted psychotropic effects.
Solution Approach 2:
The invention applies local quality by introducing specific substituents at the 4'-position of the CBD molecule while leaving the rest of the molecular structure intact. This localized modification allows the compound to gain new properties (receptor binding affinity) without completely altering the base CBD structure, thus maintaining some beneficial properties while adding therapeutic efficacy.
2Reliability
If CBD is used as a treatment, then psychoactive effects are avoided, but binding affinity to cannabinoid receptors is negligible
Solution Approach 1:
The patent changes the binding affinity parameter by substituting hydrogen at the 4'-position with various functional groups. This modification increases the molecular weight, polarity, and steric properties of the compound, enabling it to form stronger interactions with CB1 and CB2 receptors while the specific nature of substituents can be optimized to avoid excessive psychoactivity.
Solution Approach 2:
The invention introduces receptor-binding capability through localized substitution at the 4'-position, which is a specific region of the CBD molecule. This local modification creates a pharmacophore that can interact with cannabinoid receptors, while the rest of the molecule maintains properties that reduce psychoactive effects.
3Reliability
If synthetic cannabinoid derivatives are developed to improve efficacy, then therapeutic potential increases, but complexity of compound structure and synthesis increases
Solution Approach 1:
The patent systematically varies substitution parameters at the 4'-position (type of group, position, stereochemistry) to optimize therapeutic potential. By focusing changes on a single position rather than multiple positions simultaneously, the compound structure complexity is minimized while still achieving significant improvements in therapeutic efficacy.
Solution Approach 2:
The invention concentrates structural modifications at a single location (4'-position) rather than distributing changes throughout the molecule. This localized approach simplifies synthesis compared to multi-position substitution and reduces the complexity of characterizing stereoisomers, while still achieving diverse pharmacological properties through different substituent groups.
Data Source
AI summary
The present invention relates to a cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof. The cannabinoid derivative of the invention is an analogue of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivative of the invention.